James C. Padussis
YOU?
Author Swipe
View article: Supplementary Figure 2 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure 2 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 71KB, Bevacizumab does not alter in vitro LPAM chemosensitivity.
View article: Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Supplementary Figure Legend from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure Legend from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 74KB.
View article: Data from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Data from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Melanoma responds poorly to standard chemotherapy due to its intrinsic chemoresistance. Multiple genetic and molecular defects, including an activating mutation in the BRaf kinase gene, are associated with melanoma, and the resulting alter…
View article: Supplementary Figure 2 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure 2 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 71KB, Bevacizumab does not alter in vitro LPAM chemosensitivity.
View article: Supplementary Figure Legend from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure Legend from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 74KB.
View article: Data from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Data from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
Purpose: To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infus…
View article: Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 126KB, Human melanoma cells secrete VEGF which is effectively neutralized by bevacizumab.
View article: Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 126KB, Human melanoma cells secrete VEGF which is effectively neutralized by bevacizumab.
View article: Supplementary Table 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Table 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 55KB, Summary of tumor response to systemic bevacizumab and regional melphalan.
View article: Data from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Data from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
Purpose: To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infus…
View article: Data from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Data from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Melanoma responds poorly to standard chemotherapy due to its intrinsic chemoresistance. Multiple genetic and molecular defects, including an activating mutation in the BRaf kinase gene, are associated with melanoma, and the resulting alter…
View article: Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Figures 1-5 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Methods and Figure Legends from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Supplementary Table 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Supplementary Table 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Open
PDF file, 55KB, Summary of tumor response to systemic bevacizumab and regional melphalan.
View article: Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy Open
Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
View article: Geographic variation in attitudes regarding management of locally advanced pancreatic cancer
Geographic variation in attitudes regarding management of locally advanced pancreatic cancer Open
In an international survey of pancreatic surgeons, attitudes regarding locally advanced pancreatic cancer and metastatic disease management varied widely across geographic locations. Better evidence is needed to define optimal management o…
View article: Association of Gravity Drainage and Complications Following Whipple: An Analysis of the ACS-NSQIP Targeted Database
Association of Gravity Drainage and Complications Following Whipple: An Analysis of the ACS-NSQIP Targeted Database Open
Background: The optimal type of operative drainage following pancreaticoduodenectomy (PD) remains unclear. Our objective is to investigate risk associated with closed drainage techniques (passive [gravity] vs. suction) after PD. Methods: W…
View article: Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive Open
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan, and most stain posit…
View article: Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma Open
Objective: Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with orego…
View article: SAT-121 Immediate Dysglycemia After Pancreatic Resection: Prevalence and Risk Factors
SAT-121 Immediate Dysglycemia After Pancreatic Resection: Prevalence and Risk Factors Open
Introduction: Postoperative hyper- and hypoglycemia are associated with increased morbidity and mortality following many types of surgical procedures. Long-term development of diabetes mellitus (DM) following pancreatic resection is well d…